rocuronium 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
neuromuscular blocking agents with rigid structure	2396	119302-91-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ORG-9426 ORG 9426 rocuronium rocuronium bromide zemuron esmeron	Rocuronium bromide is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. It acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium. Molecular weight: 529.79 Formula: C32H53N2O4 CLOGP: 2.23 LIPINSKI: 1 HAC: 6 HDO: 1 TPSA: 59 ALOGS: -7.30 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ORG-9426
ORG 9426
rocuronium
rocuronium bromide
zemuron
esmeron

Rocuronium bromide is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. It acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium.

Molecular weight: 529.79
Formula: C32H53N2O4
CLOGP: 2.23
LIPINSKI: 1
HAC: 6
HDO: 1
TPSA: 59
ALOGS: -7.30
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	17 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.38 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.21 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3.70 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.54 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.60 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
March 17, 1994	FDA	ORGANON USA INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic reaction	1365.75	28.97	469	8724	53586	50542345
Anaphylactic shock	950.95	28.97	282	8911	19873	50576058
Cardiac arrest	420.89	28.97	233	8960	83418	50512513
Hypotension	404.07	28.97	336	8857	235133	50360798
Neuromuscular block prolonged	400.78	28.97	71	9122	440	50595491
Bronchospasm	381.21	28.97	131	9062	14723	50581208
Circulatory collapse	238.98	28.97	101	9092	19899	50576032
Serotonin syndrome	234.20	28.97	106	9087	24607	50571324
Delayed recovery from anaesthesia	204.74	28.97	43	9150	706	50595225
Tachycardia	188.22	28.97	151	9042	99612	50496319
Stress cardiomyopathy	184.61	28.97	65	9128	7822	50588109
Bradycardia	150.95	28.97	111	9082	64315	50531616
Drug interaction	149.03	28.97	182	9011	199439	50396492
Therapeutic product effect prolonged	121.17	28.97	24	9169	289	50595642
Myoglobin urine present	115.91	28.97	24	9169	366	50595565
Recurrence of neuromuscular blockade	112.58	28.97	19	9174	84	50595847
Hypoventilation	106	28.97	36	9157	3885	50592046
Wrist surgery	103.93	28.97	25	9168	773	50595158
Finger deformity	100.13	28.97	38	9155	5644	50590287
Unwanted awareness during anaesthesia	99.21	28.97	20	9173	265	50595666
Airway peak pressure increased	98.52	28.97	20	9173	275	50595656
Ventricular tachycardia	90.13	28.97	48	9145	15773	50580158
Neuromuscular blockade	87.08	28.97	18	9175	272	50595659
Fatigue	86.49	28.97	13	9180	707588	49888343
Pulseless electrical activity	83.14	28.97	35	9158	6806	50589125
Urticaria	82.01	28.97	109	9084	129452	50466479
Breast cancer recurrent	80.07	28.97	29	9164	3779	50592152
Blood pressure decreased	79.38	28.97	72	9121	55837	50540094
Paralysis	78.32	28.97	36	9157	8628	50587303
Oxygen saturation decreased	75.26	28.97	79	9114	73169	50522762
Tenosynovitis	74.47	28.97	37	9156	10528	50585403
Limb operation	68.43	28.97	25	9168	3339	50592592
Amylase increased	63.38	28.97	27	9166	5403	50590528
Diarrhoea	60.97	28.97	16	9177	588460	50007471
Anaphylactoid reaction	60.80	28.97	23	9170	3383	50592548
Hyperthermia malignant	60.64	28.97	16	9177	723	50595208
Ventricular fibrillation	60.03	28.97	32	9161	10527	50585404
Toxic encephalopathy	59.70	28.97	26	9167	5489	50590442
Arthralgia	58.47	28.97	6	9187	438696	50157235
Hypoxia	57.66	28.97	58	9135	51065	50544866
Apnoea	56.93	28.97	27	9166	6939	50588992
Dystonia	56.38	28.97	32	9161	11894	50584037
Anaesthetic complication	55.19	28.97	18	9175	1712	50594219
Nausea	55.11	28.97	30	9163	705368	49890563
Headache	53.92	28.97	13	9180	506522	50089409
Haemodynamic instability	53.31	28.97	27	9166	7997	50587934
Type I hypersensitivity	53.29	28.97	19	9174	2366	50593565
Anaphylactoid shock	52.10	28.97	12	9181	306	50595625
Premature delivery	51.37	28.97	39	9154	23624	50572307
Maternal exposure during delivery	51.31	28.97	15	9178	991	50594940
Troponin increased	50.12	28.97	26	9167	8092	50587839
Procedural hypotension	49.96	28.97	15	9178	1087	50594844
Exposure during pregnancy	49.46	28.97	83	9110	120932	50474999
Endotracheal intubation complication	49.27	28.97	12	9181	391	50595540
Postoperative delirium	47.82	28.97	9	9184	81	50595850
Subcutaneous emphysema	46.28	28.97	13	9180	744	50595187
Airway complication of anaesthesia	45.69	28.97	10	9183	201	50595730
Hyperreflexia	45.42	28.97	21	9172	5097	50590834
Skin test positive	43.49	28.97	12	9181	643	50595288
Angioedema	42.94	28.97	43	9150	37633	50558298
Diabetes insipidus	42.33	28.97	16	9177	2348	50593583
Vasoplegia syndrome	41.33	28.97	13	9180	1101	50594830
Fall	41.11	28.97	6	9187	334926	50261005
Muscle rigidity	40.17	28.97	24	9169	9805	50586126
Blood lactate dehydrogenase increased	39.74	28.97	31	9162	19531	50576400
Tracheal injury	39.54	28.97	7	9186	43	50595888
Laryngeal oedema	39.51	28.97	19	9174	5034	50590897
Respiratory acidosis	39.21	28.97	20	9173	6008	50589923
Clonus	36.64	28.97	17	9176	4158	50591773
Torsade de pointes	36.08	28.97	24	9169	11811	50584120
Anticholinergic syndrome	35.25	28.97	13	9180	1782	50594149
Myasthenic syndrome	35.12	28.97	8	9185	194	50595737
Atrioventricular dissociation	34.22	28.97	8	9185	218	50595713
Vomiting	33.88	28.97	21	9172	460737	50135194
Pulmonary oedema	33.73	28.97	43	9150	48895	50547036
Altered state of consciousness	32.61	28.97	29	9164	21881	50574050
Post procedural stroke	31.78	28.97	6	9187	55	50595876
Cardiac output decreased	31.30	28.97	10	9183	890	50595041
Coronary artery embolism	30.56	28.97	7	9186	174	50595757
Muscle twitching	30.36	28.97	24	9169	15407	50580524
Laryngospasm	30.16	28.97	13	9180	2675	50593256
Therapeutic product effect increased	30.11	28.97	10	9183	1006	50594925
Blood creatine phosphokinase increased	29.87	28.97	30	9163	26337	50569594
Spirometry abnormal	29.43	28.97	7	9186	206	50595725
Blood potassium increased	29.08	28.97	24	9169	16374	50579557

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	730.06	23.76	232	8151	13104	29553040
Anaphylactic reaction	655.77	23.76	258	8125	27315	29538829
Hyperthermia malignant	377.33	23.76	90	8293	1694	29564450
Neuromuscular block prolonged	313.99	23.76	61	8322	402	29565742
Hypotension	233.38	23.76	280	8103	194074	29372070
Bronchospasm	183.37	23.76	77	8306	9532	29556612
Cardiac arrest	180.65	23.76	167	8216	85424	29480720
Recurrence of neuromuscular blockade	162.74	23.76	29	8354	109	29566035
Bradycardia	142.10	23.76	130	8253	65499	29500645
Delayed recovery from anaesthesia	134.96	23.76	33	8350	690	29565454
Pulseless electrical activity	101.20	23.76	45	8338	6389	29559755
Kounis syndrome	100.50	23.76	32	8351	1797	29564347
Negative pressure pulmonary oedema	95.23	23.76	20	8363	203	29565941
Tachycardia	92.32	23.76	108	8275	72302	29493842
Neuromuscular blockade	91.46	23.76	19	8364	182	29565962
Respiratory depression	90.19	23.76	53	8330	13470	29552674
Electrocardiogram ST segment elevation	85.66	23.76	36	8347	4456	29561688
Anaesthetic complication	83.18	23.76	24	8359	962	29565182
Blood pressure decreased	81.04	23.76	81	8302	45396	29520748
Haemodynamic instability	76.82	23.76	40	8343	8033	29558111
Arteriospasm coronary	75.00	23.76	28	8355	2537	29563607
Hypoventilation	68.68	23.76	27	8356	2814	29563330
Fatigue	67.99	23.76	6	8377	316815	29249329
Procedural hypotension	67.74	23.76	20	8363	870	29565274
Oxygen saturation decreased	67.41	23.76	73	8310	44864	29521280
Airway complication of anaesthesia	67.12	23.76	14	8369	137	29566007
Endotracheal intubation complication	61.13	23.76	15	8368	318	29565826
Circulatory collapse	61.03	23.76	47	8336	18626	29547518
Serotonin syndrome	57.06	23.76	44	8339	17468	29548676
Ventricular fibrillation	56.50	23.76	42	8341	15791	29550353
Respiratory arrest	55.42	23.76	51	8332	25782	29540362
Ventricular tachycardia	55.23	23.76	48	8335	22526	29543618
Hypoxia	51.09	23.76	65	8318	47314	29518830
Airway peak pressure increased	47.63	23.76	8	8375	19	29566125
Pulmonary alveolar haemorrhage	45.15	23.76	26	8357	6354	29559790
Unwanted awareness during anaesthesia	44.49	23.76	8	8375	32	29566112
Rhabdomyolysis	44.11	23.76	69	8314	60739	29505405
Respiratory acidosis	42.76	23.76	22	8361	4306	29561838
Intensive care unit acquired weakness	41.70	23.76	14	8369	929	29565215
Death	41.20	23.76	23	8360	342061	29224083
Burkholderia test positive	40.91	23.76	14	8369	985	29565159
Brain oedema	40.45	23.76	31	8352	12189	29553955
Hypoxic-ischaemic encephalopathy	40.10	23.76	21	8362	4263	29561881
Cardio-respiratory arrest	38.91	23.76	59	8324	50542	29515602
Urticaria	38.22	23.76	61	8322	54599	29511545
Pulmonary oedema	37.44	23.76	53	8330	42682	29523462
Anaesthetic complication neurological	36.97	23.76	10	8373	315	29565829
Multiple organ dysfunction syndrome	36.88	23.76	65	8318	63051	29503093
Thyrotoxic crisis	35.99	23.76	10	8373	349	29565795
Respiratory failure	35.20	23.76	82	8301	97049	29469095
Acidosis	35.18	23.76	26	8357	9679	29556465
Hypotonic-hyporesponsive episode	34.22	23.76	6	8377	20	29566124
Tachypnoea	32.71	23.76	30	8353	15085	29551059
Propofol infusion syndrome	31.84	23.76	11	8372	796	29565348
Endotracheal intubation	30.57	23.76	15	8368	2654	29563490
Blood catecholamines increased	30.36	23.76	5	8378	10	29566134
Diarrhoea	30.19	23.76	30	8353	332668	29233476
Fall	29.54	23.76	7	8376	177171	29388973
Drug reaction with eosinophilia and systemic symptoms	29.51	23.76	38	8345	27954	29538190
Muscle rigidity	29.24	23.76	23	8360	9388	29556756
Arthralgia	28.92	23.76	3	8380	139614	29426530
Drug ineffective	28.00	23.76	187	8196	362983	29203161
Trigemino-cardiac reflex	27.54	23.76	7	8376	172	29565972
Dizziness	27.06	23.76	10	8373	189674	29376470
Product measured potency issue	26.79	23.76	6	8377	84	29566060
Therapeutic product effect decreased	26.49	23.76	37	8346	29414	29536730
Apnoea	25.91	23.76	18	8365	6084	29560060
Catecholamine crisis	25.58	23.76	5	8378	34	29566110
Anaphylactoid reaction	25.52	23.76	12	8371	1933	29564211
Therapeutic product effect prolonged	25.48	23.76	7	8376	234	29565910
Headache	25.11	23.76	9	8374	173998	29392146
Oromandibular dystonia	24.87	23.76	8	8375	464	29565680
Hyperkalaemia	24.63	23.76	54	8329	61338	29504806
Electrocardiogram ST segment depression	24.20	23.76	12	8371	2173	29563971

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic reaction	1830.91	22.35	681	16065	67983	64414003
Anaphylactic shock	1590.69	22.35	500	16246	29828	64452158
Neuromuscular block prolonged	675.62	22.35	129	16617	848	64481138
Hypotension	548.23	22.35	578	16168	380396	64101590
Cardiac arrest	532.65	22.35	386	16360	153678	64328308
Bronchospasm	510.10	22.35	197	16549	21485	64460501
Hyperthermia malignant	421.55	22.35	103	16643	2356	64479630
Delayed recovery from anaesthesia	308.25	22.35	73	16673	1455	64480531
Circulatory collapse	262.88	22.35	142	16604	33590	64448396
Tachycardia	253.83	22.35	249	16497	149330	64332656
Serotonin syndrome	253.31	22.35	146	16600	39136	64442850
Bradycardia	245.08	22.35	220	16526	117999	64363987
Recurrence of neuromuscular blockade	218.56	22.35	39	16707	165	64481821
Pulseless electrical activity	178.35	22.35	80	16666	12659	64469327
Stress cardiomyopathy	175.33	22.35	72	16674	9185	64472801
Neuromuscular blockade	154.54	22.35	34	16712	480	64481506
Blood pressure decreased	152.54	22.35	147	16599	86052	64395934
Hypoventilation	139.06	22.35	54	16692	5952	64476034
Airway peak pressure increased	133.63	22.35	28	16718	309	64481677
Fatigue	132.14	22.35	19	16727	748711	63733275
Ventricular tachycardia	132.03	22.35	92	16654	34173	64447813
Oxygen saturation decreased	125.93	22.35	147	16599	107029	64374957
Procedural hypotension	123.55	22.35	37	16709	1849	64480137
Drug interaction	122.86	22.35	282	16464	361801	64120185
Airway complication of anaesthesia	122.47	22.35	27	16719	385	64481601
Kounis syndrome	122.00	22.35	41	16705	2984	64479002
Haemodynamic instability	119.51	22.35	64	16682	14848	64467138
Anaesthetic complication	116.18	22.35	38	16708	2541	64479445
Electrocardiogram ST segment elevation	115.87	22.35	50	16696	7209	64474777
Ventricular fibrillation	110.94	22.35	72	16674	23788	64458198
Unwanted awareness during anaesthesia	109.09	22.35	23	16723	262	64481724
Negative pressure pulmonary oedema	102.46	22.35	21	16725	206	64481780
Urticaria	100.55	22.35	155	16591	147162	64334824
Therapeutic product effect prolonged	95.02	22.35	23	16723	504	64481482
Myoglobin urine present	92.44	22.35	23	16723	567	64481419
Hypoxia	88.98	22.35	112	16634	88037	64393949
Endotracheal intubation complication	88.02	22.35	23	16723	693	64481293
Diarrhoea	86.47	22.35	40	16706	722664	63759322
Arthralgia	83.25	22.35	9	16737	442251	64039735
Paralysis	82.49	22.35	46	16700	11549	64470437
Arteriospasm coronary	81.87	22.35	36	16710	5429	64476557
Anaphylactoid reaction	76.81	22.35	33	16713	4705	64477281
Respiratory depression	76.67	22.35	57	16689	23386	64458600
Headache	75.56	22.35	22	16724	529445	63952541
Apnoea	73.19	22.35	41	16705	10381	64471605
Respiratory acidosis	72.58	22.35	40	16706	9815	64472171
Fall	72.36	22.35	11	16735	416815	64065171
Respiratory arrest	71.23	22.35	78	16668	52907	64429079
Nausea	69.99	22.35	61	16685	785739	63696247
Pulmonary oedema	65.53	22.35	91	16655	78583	64403403
Wrist surgery	64.09	22.35	18	16728	715	64481271
Muscle rigidity	62.84	22.35	45	16701	17428	64464558
Diabetes insipidus	62.01	22.35	28	16718	4493	64477493
Dystonia	55.35	22.35	43	16703	18822	64463164
Type I hypersensitivity	55.01	22.35	24	16722	3550	64478436
Pain in extremity	54.91	22.35	7	16739	303078	64178908
Anticholinergic syndrome	54.78	22.35	22	16724	2647	64479339
Decreased appetite	54.76	22.35	5	16741	281284	64200702
Anaphylactoid shock	54.66	22.35	16	16730	738	64481248
Vomiting	53.72	22.35	39	16707	551078	63930908
Skin test positive	53.49	22.35	17	16729	1036	64480950
Death	52.71	22.35	30	16716	482675	63999311
Laryngospasm	52.59	22.35	23	16723	3422	64478564
Dizziness	52.58	22.35	23	16723	430140	64051846
Finger deformity	52.34	22.35	26	16720	5160	64476826
Trigemino-cardiac reflex	51.00	22.35	12	16734	232	64481754
Anaesthetic complication neurological	50.47	22.35	14	16732	531	64481455
Postoperative delirium	49.43	22.35	11	16735	164	64481822
Multiple organ dysfunction syndrome	47.07	22.35	90	16656	101323	64380663
Respiratory failure	46.35	22.35	118	16628	161065	64320921
Angioedema	46.31	22.35	68	16678	61753	64420233
Neutropenia	44.71	22.35	5	16741	239619	64242367
Hypoxic-ischaemic encephalopathy	44.49	22.35	26	16720	7126	64474860
Amylase increased	44.45	22.35	29	16717	9656	64472330
Pulmonary alveolar haemorrhage	44.30	22.35	29	16717	9709	64472277
Maternal exposure during delivery	43.69	22.35	14	16732	876	64481110
Carcinoid crisis	43.60	22.35	12	16734	442	64481544
Erythema	42.86	22.35	126	16620	186944	64295042
Subcutaneous emphysema	42.75	22.35	16	16730	1593	64480393
Laryngeal oedema	42.00	22.35	25	16721	7088	64474898
Procedural complication	41.51	22.35	25	16721	7240	64474746
Anaesthetic complication pulmonary	40.72	22.35	8	16738	62	64481924
Thyrotoxic crisis	40.58	22.35	14	16732	1102	64480884
Limb operation	40.42	22.35	18	16728	2796	64479190
Back pain	40.30	22.35	8	16738	250163	64231823
Clonus	40.26	22.35	23	16723	6044	64475942
Asthenia	39.48	22.35	32	16714	428012	64053974
Procedural haemorrhage	39.05	22.35	20	16726	4232	64477754
Weight decreased	38.66	22.35	13	16733	285726	64196260
Acidosis	38.51	22.35	34	16712	17761	64464225
Atrioventricular dissociation	37.84	22.35	10	16736	315	64481671
Pruritus	37.67	22.35	17	16729	312383	64169603
Shock	37.61	22.35	48	16698	38192	64443794
Malaise	37.32	22.35	29	16717	396218	64085768
Product measured potency issue	37.32	22.35	9	16737	194	64481792
Rhabdomyolysis	37.26	22.35	77	16669	91649	64390337
Atrioventricular block second degree	36.33	22.35	22	16724	6432	64475554
Propofol infusion syndrome	35.52	22.35	14	16732	1603	64480383
Upper airway obstruction	35.22	22.35	13	16733	1245	64480741
Tracheal injury	35.21	22.35	7	16739	58	64481928
Endotracheal intubation	34.85	22.35	18	16728	3877	64478109
Toxic encephalopathy	34.65	22.35	25	16721	9790	64472196
Intensive care unit acquired weakness	34.63	22.35	14	16732	1713	64480273
Anaemia	34.06	22.35	29	16717	378651	64103335
Exposure during pregnancy	33.68	22.35	67	16679	77608	64404378
Torsade de pointes	33.30	22.35	31	16715	17332	64464654
Hypercapnia	32.79	22.35	22	16724	7672	64474314
Dehydration	32.74	22.35	8	16738	216755	64265231
Tenosynovitis	32.62	22.35	26	16720	11807	64470179
Cardio-respiratory arrest	32.48	22.35	76	16670	98317	64383669
Troponin increased	32.48	22.35	29	16717	15370	64466616
Hypertensive crisis	31.99	22.35	31	16715	18217	64463769
Hyperreflexia	31.82	22.35	21	16725	7127	64474859
Hypotonia	31.69	22.35	25	16721	11187	64470799
Pain	31.51	22.35	60	16686	553451	63928535
Vasoplegia syndrome	31.31	22.35	15	16731	2752	64479234
Abdominal discomfort	31.15	22.35	5	16741	182317	64299669
Gait disturbance	31.09	22.35	4	16742	172151	64309835
Insomnia	30.47	22.35	7	16739	197829	64284157
Tachypnoea	30.40	22.35	36	16710	26535	64455451
Atrioventricular block complete	30.11	22.35	27	16719	14391	64467595
Premature delivery	29.66	22.35	30	16716	18559	64463427
Coronary artery embolism	29.24	22.35	8	16738	288	64481698
Completed suicide	28.99	22.35	11	16735	224403	64257583
Phaeochromocytoma crisis	28.95	22.35	8	16738	299	64481687
Pneumonia	28.20	22.35	65	16681	559511	63922475
Spinal cord infarction	28.06	22.35	9	16737	565	64481421
Blood catecholamines increased	26.42	22.35	5	16741	31	64481955
Catecholamine crisis	26.02	22.35	5	16741	34	64481952
COVID-19 treatment	25.98	22.35	8	16738	439	64481547
Post procedural stroke	25.95	22.35	6	16740	107	64481879
Resuscitation	25.92	22.35	12	16734	2039	64479947
Infection	25.72	22.35	8	16738	184872	64297114
Abdominal pain	25.62	22.35	26	16720	312349	64169637
Muscle twitching	25.57	22.35	28	16718	18970	64463016
Post procedural haemorrhage	25.41	22.35	23	16723	12408	64469578
Abdominal pain upper	25.39	22.35	7	16739	175023	64306963
Constipation	25.34	22.35	14	16732	229323	64252663
Sinusitis	24.93	22.35	4	16742	145924	64336062
Electrocardiogram ST segment depression	24.81	22.35	15	16731	4374	64477612
Renal injury	24.80	22.35	25	16721	15404	64466582
Paraplegia	24.49	22.35	15	16731	4475	64477511
Urinary tract infection	24.36	22.35	15	16731	231581	64250405
Fear	24.19	22.35	28	16718	20143	64461843
Ventricular arrhythmia	24.17	22.35	18	16728	7397	64474589
Spirometry abnormal	23.99	22.35	8	16738	568	64481418
Therapeutic product effect increased	23.94	22.35	10	16736	1330	64480656
Pulse absent	23.26	22.35	19	16727	8927	64473059
Myasthenic syndrome	23.10	22.35	8	16738	637	64481349
Febrile neutropenia	22.93	22.35	10	16736	187647	64294339
Hypothermia	22.88	22.35	27	16719	19829	64462157
Procedural vomiting	22.76	22.35	8	16738	666	64481320
Metabolic acidosis	22.53	22.35	54	16692	70904	64411082
Neuroleptic malignant syndrome	22.44	22.35	30	16716	24966	64457020

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	M03AC09	MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS Other quaternary ammonium compounds
MeSH PA	D009465	Neuromuscular Agents
MeSH PA	D009466	Neuromuscular Blocking Agents
MeSH PA	D003473	Neuromuscular Nondepolarizing Agents
MeSH PA	D018373	Peripheral Nervous System Agents
CHEBI has role	CHEBI:51371	muscle relaxants
FDA EPC	N0000175720	Nondepolarizing Neuromuscular Blocker
FDA PE	N0000175732	Neuromuscular Nondepolarizing Blockade

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Muscle relaxation, function	indication	11977004
General anesthesia	indication	50697003
Skeletal Muscle Relaxation for Endotracheal Intubation	indication
Respiratory acidosis	contraindication	12326000
Alkalosis	contraindication	21420006
Acidosis	contraindication	51387008
Eaton-Lambert syndrome	contraindication	56989000	DOID:0050214
Pulmonary hypertension	contraindication	70995007	DOID:6432
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Respiratory alkalosis	contraindication	111378004
Disease of liver	contraindication	235856003	DOID:409
Disorder of electrolytes	contraindication	237840007
Malignant hyperthermia	contraindication	405501007

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.61	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Acetylcholine receptor	Ion channel	P02708 P11230 Q07001	ACHA_HUMAN ACHB_HUMAN ACHD_HUMAN	ANTAGONIST	IC50	7.77		WOMBAT-PK	CHEMBL
Acetylcholine receptor; alpha1/beta1/delta/gamma	Ion channel	P02708 P07510 P11230 Q07001	ACHA_HUMAN ACHG_HUMAN ACHB_HUMAN ACHD_HUMAN		IC50	7.09		CHEMBL

External reference:

ID	Source
D00765	KEGG_DRUG
4020866	VANDF
C0209337	UMLSCUI
CHEBI:8885	CHEBI
CHEMBL1201244	ChEMBL_ID
CHEMBL1200648	ChEMBL_ID
D000077123	MESH_DESCRIPTOR_UI
DB00728	DRUGBANK_ID
4003	IUPHAR_LIGAND_ID
WRE554RFEZ	UNII
441290	PUBCHEM_CID
151718	RXNORM
1460	MMSL
159147	MMSL
5433	MMSL
d03766	MMSL
004442	NDDF
013418	NDDF
108449002	SNOMEDCT_US
108450002	SNOMEDCT_US
372494005	SNOMEDCT_US
6864	INN_ID
143558-00-3	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Rocuronium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9250	INJECTION	10 mg	INTRAVENOUS	ANDA	26 sections
Rocuronium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9250	INJECTION	10 mg	INTRAVENOUS	ANDA	26 sections
Rocuronium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9251	INJECTION	10 mg	INTRAVENOUS	ANDA	26 sections
Rocuronium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9251	INJECTION	10 mg	INTRAVENOUS	ANDA	26 sections
Rocuronium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	0409-9558	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	26 sections
Rocuronium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	0409-9558	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	26 sections
Rocuronium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3220	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	26 sections
rocuronium bromide	HUMAN PRESCRIPTION DRUG LABEL	1	25021-662	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	27 sections
rocuronium bromide	HUMAN PRESCRIPTION DRUG LABEL	1	39822-4200	SOLUTION	10 mg	INTRAVENOUS	ANDA	26 sections
Rocuronium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	43066-007	INJECTION	50 mg	INTRAVENOUS	ANDA	26 sections
Rocuronium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	43066-013	INJECTION	100 mg	INTRAVENOUS	ANDA	26 sections
ROCURONIUM BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	43547-530	INJECTION	50 mg	INTRAVENOUS	ANDA	25 sections
ROCURONIUM BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	43547-531	INJECTION	100 mg	INTRAVENOUS	ANDA	25 sections
ROCURONIUM BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1354	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	18 sections
ROCURONIUM BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1355	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	18 sections
ROCURONIUM BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1545	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	17 sections
ROCURONIUM BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1546	INJECTION, SOLUTION	50 mg	INTRAVENOUS	ANDA	17 sections
Rocuronium Bromide	Human Prescription Drug Label	1	55150-225	INJECTION, SOLUTION	50 mg	INTRAVENOUS	ANDA	25 sections
Rocuronium Bromide	Human Prescription Drug Label	1	55150-226	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	25 sections
Rocuronium	HUMAN PRESCRIPTION DRUG LABEL	1	63323-426	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	26 sections
Rocuronium	HUMAN PRESCRIPTION DRUG LABEL	1	65219-065	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	26 sections
Rocuronium	HUMAN PRESCRIPTION DRUG LABEL	1	66794-228	INJECTION, SOLUTION	50 mg	INTRAVENOUS	ANDA	17 sections
Rocuronium	HUMAN PRESCRIPTION DRUG LABEL	1	66794-229	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	17 sections
Rocuronium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	67457-228	INJECTION	10 mg	INTRAVENOUS	ANDA	26 sections
Rocuronium Bromide	Human Prescription Drug Label	1	68083-364	INJECTION	10 mg	INTRAVENOUS	ANDA	26 sections
Rocuronium Bromide	Human Prescription Drug Label	1	68083-365	INJECTION	10 mg	INTRAVENOUS	ANDA	26 sections
Rocuronium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	70860-651	SOLUTION	10 mg	INTRAVENOUS	ANDA	27 sections
Rocuronium bromide	HUMAN PRESCRIPTION DRUG LABEL	1	71479-004	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	29 sections
Rocuronium bromide	HUMAN PRESCRIPTION DRUG LABEL	1	71479-005	INJECTION, SOLUTION	50 mg	INTRAVENOUS	ANDA	29 sections
rocuronium bromide	HUMAN PRESCRIPTION DRUG LABEL	1	71872-7036	SOLUTION	10 mg	INTRAVENOUS	ANDA	26 sections